SHIRE PLC
|
||||
By:
|
/s/ James Bowling
|
|||
Name: |
James Bowling
|
|||
Title: |
Interim Chief Financial Officer
|
EXHIBIT INDEX
|
|
Number
|
Description
|
99.1
|
Press release dated April 15, 2014
|
Pre-quarterly Results Communication
|
|
www.shire.com
|
Quarter average rate
|
Q1 2013
|
Q2 2013
|
Q3 2013
|
Q4 2013
|
Q1 2014
|
USD:£1
|
1.58
|
1.53
|
1.53
|
1.62
|
1.66
|
USD:€1
|
1.33
|
1.30
|
1.32
|
1.36
|
1.37
|
USD:CHF1
|
1.09
|
1.06
|
1.07
|
1.10
|
1.12
|
FX impact on Revenue
|
0%
|
-1%
|
0%
|
0%
|
-1%
|
YTD average rate
|
Q1 2013
|
HY 2013
|
9m 2013
|
FY 2013
|
Q1 2014
|
USD:£1
|
1.58
|
1.55
|
1.55
|
1.56
|
1.66
|
USD:€1
|
1.33
|
1.31
|
1.31
|
1.33
|
1.37
|
USD:CHF1
|
1.09
|
1.07
|
1.07
|
1.08
|
1.12
|
FX impact on Revenue
|
0%
|
0%
|
0%
|
0%
|
-1%
|
Currency
|
Impact on 2014 Full Year Guidance Non GAAP EPS
|
Pound Sterling
|
10 cents movement in average exchange rate for full year impacts EPS by approximately +/- 0%
|
Euro
|
10 cents movement in average exchange rate for full year impacts EPS by approximately +/- 2%
|
Swiss Franc
|
10 cents movement in average exchange rate for full year impacts EPS by approximately +/- 0%
|
in millions
|
Q1 2013
|
Q2 2013
|
Q3 2013
|
Q4 2013
|
Q1 2014 estimated
|
Basic WANS (1)
|
551.5
|
549.6
|
548.4
|
558.0
|
584.3
|
Share based employee awards
|
3.8
|
2.6
|
3.5
|
4.9
|
4-6m
|
Convertible Bonds
|
33.6
|
33.8
|
33.8
|
27.7
|
0
|
Diluted WANS
|
588.9
|
586.0
|
585.7
|
590.6
|
|
Note: YTD Diluted WANS
|
588.9
|
587.5
|
587.5
|
590.3
|
|
(1)
|
Excludes shares purchased by the Employee Benefit Trust and under the share buy-back program, presented by Shire as treasury stock.
|
|
·
|
Shire’s products may not be a commercial success;
|
|
·
|
revenues from ADDERALL XR are subject to generic erosion and revenues from INTUNIV will become subject to generic competition starting in December 2014;
|
|
·
|
the failure to obtain and maintain reimbursement, or an adequate level of reimbursement, by third-party payors in a timely manner for Shire's products may impact future revenues, financial condition and results of operations;
|
|
·
|
Shire conducts its own manufacturing operations for certain of its Rare Diseases products and is reliant on third party contractors to manufacture other products and to provide goods and services. Some of Shire’s products or ingredients are only available from a single approved source for manufacture. Any disruption to the supply chain for any of Shire’s products may result in Shire being unable to continue marketing or developing a product or may result in Shire being unable to do so on a commercially viable basis for some period of time.
|
|
·
|
the development, approval and manufacturing of Shire’s products is subject to extensive oversight by various regulatory agencies and regulatory approvals or interventions associated with changes to manufacturing sites, ingredients or manufacturing processes could lead to significant delays, increase in operating costs, lost product sales, an interruption of research activities or the delay of new product launches;
|
|
·
|
the actions of certain customers could affect Shire's ability to sell or market products profitably. Fluctuations in buying or distribution patterns by such customers can adversely impact Shire’s revenues, financial conditions or results of operations;
|
|
·
|
investigations or enforcement action by regulatory authorities or law enforcement agencies relating to Shire’s activities in the highly regulated markets in which it operates may result in the distraction of senior management, significant legal costs and the payment of substantial compensation or fines;
|
|
·
|
adverse outcomes in legal matters and other disputes, including Shire’s ability to enforce and defend patents and other intellectual property rights required for its business, could have a material adverse effect on Shire’s revenues, financial condition or results of operations;
|
|
·
|
Shire faces intense competition for highly qualified personnel from other companies, academic institutions, government entities and other organizations. Shire is undergoing a corporate reorganization and the consequent uncertainty could adversely impact Shire’s ability to attract and/or retain the highly skilled personnel needed for Shire to meet its strategic objectives;
|
|
·
|
failure to achieve Shire’s strategic objectives with respect to the acquisition of ViroPharma Incorporated may adversely affect Shire’s financial condition and results of operations;
|